^
Association details:
| Biomarker: | BRAF amplification |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Excerpt:
An acquired resistance mechanism activating the MAPK pathway was identified in 9 of 11 Prog tumours (82%; Table 1; Fig. 1); BRAF amplifications were detected in 4 (36%), MEK1/2 mutations in 3 (27%) and oncogenic NRAS mutations in 3 (27%) Prog tumours (Figs 1 and 2).
DOI:
10.1038/ncomms6694
Trial ID:
